Viscosupplementation Market Size, Share & Trends Report

Viscosupplementation Market Size, Share & Trends Analysis Report By Product (Single Injection, Three Injection, Five Injection), By Region, And Segment Forecasts, 2019 - 2026

  • Published Date: May, 2019
  • Base Year for Estimate: 2018
  • Report ID: GVR-1-68038-982-1
  • Format: Electronic (PDF)
  • Historical Data: 2015 - 2017
  • Number of Pages: 155

Industry Insights

The global viscosupplementation market size was valued at around USD 3.6 billion in 2018 and is projected to expand at CAGR of 9.11% over the forecast period. The increasing geriatric population, rising prevalence of osteoarthritis and lifestyle-induced disorders, such as obesity, are some factors expected to drive the growth. According to the Caspian Journal of Internal Medicine, around 13% of women and 10% of men suffer from osteoarthritis. In 2000, the American Rheumatism Association (ACR) recognized hyaluronic acid injections i.e. viscosupplementations as the first-line treatment for osteoarthritis.

Favorable reimbursement scenario is expected to make treatment for osteoarthritis more affordable in near future. Medicare reimburses 80% of the patient allowable cost and the remaining 20% depends on patients’ secondary insurer. France has a well-defined reimbursement policy, thus, the country holds a high share in Europe. There are 13 viscosupplementations available in the country, out of which 12 are reimbursed up to 65% by Social Security, for the treatment of knee osteoarthritis. According to the International Society of Arthroscopy, Knee Surgery, and Orthopedic Sports Medicine (ISAKOS) in France, the products are reimbursed 50% of their price, which was approved in 2001.

U.S. viscosupplementation market

Presence of a strong product pipeline portfolio provides an opportunity for market expansion over the forecast period. Carbylan initiated second Phase 3 in 2016 focused on osteoarthritis treatment with and without Hydros-TA. Phase 2 provided positive results thus boosting Phase 3 trials.

As per the Osteoarthritis Research Society International (OARSI) U.S., both corticosteroids and hyaluronic acid injections can be used for the treatment of osteoarthritis, but the effect of viscosupplementation is slightly higher than that of corticosteroids. The regulatory barriers are relatively low in countries such as South Korea, which makes it an attractive marketplace for the industry players to set their footprint. Viscosupplementation is classified as specialized medication in South Korea.

Product Insights

Based on product, the viscosupplementation market is segmented into single injection, three injection, and five injection. Due to growing demand for shorter regimen, single-injection cycles are expected to register the fastest CAGR over the forecast period.

MONOVISC from Anika Therapeutics is a single-injection hyaluronic acid that received the U.S. Food and Drug Administration (FDA) approval in early 2014. Another single-injection product CINGAL, from the same company is in the pipeline. Gel-One by Zimmer Holdings and Synvisc-One by Sanofi, are other convenient single injections available in the market.

Regional Insights

The improvement of healthcare facilities due to economic development in the emerging countries, such as China, Japan, South Korea, and India, has projected Asia Pacific as the potentially lucrative market. Japan was the largest regional market in 2018. High awareness levels about single-injection treatment and greater preference for minimally invasive management of osteoarthritis is expected to drive regional growth.

Global viscosupplementation market

Europe is anticipated to observe the fastest growth in the forthcoming years. While efficacy and safety are rated in other parts of the world, Europeans view reimbursement and pricing as the decisive factors while choosing the hyaluronic acid treatment. The overall trend prevailing amongst doctors is to avoid knee replacement surgeries as far as possible, which has boosted demand for pain management through viscosupplementation.

Viscosupplementation Market Share Insights

There is a steady growth in the market with the entry of new players. Various manufacturers operating in the market are in the process of introducing new products. For instance, HAppyCross, HAppyVisc, and HAppyMini are a few products by Labrha, a France-based company. Moreover, HAppySoft (generic product) and HAppyOne (single intra-articular injection) are in the pipeline.

While there are new entrants, the existing players are strengthening their foothold by introducing new and improved products. In March 2019, in Italy, Seikagaku Corporation launched a new intra-articular single-injection viscosupplement named HyLink for the treatment of knee osteoarthritis.

In June 2016, Anika Therapeutics, Inc. launched CINGAL in Europe. The company intended to make the product available in Germany, Poland, Italy, Czech Republic, and Hungary. The product received CE mark in March 2016. It marks an important initiative in the company’s global expansion. The company presented efficacy data for CINGAL in the 2017 European Federation of National Associations of Orthopaedics and Traumatology Annual Congress, in May 2017. The company is working on getting FDA approval to launch their product in U.S.

Some key contributors operating in the market are Sanofi; Anika Therapeutics, Inc.; Seikagaku Corporation; Zimmer Holdings Inc.; Bioventus, Ferring B.V.; Lifecore Biomedical, LLC; and LG Life Sciences Ltd.

Report Scope



Base year for estimation


Actual estimates/Historical data

2015 - 2017

Forecast period

2019 - 2026

Market representation

Revenue in USD Million & CAGR from 2019 to 2026

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Country scope

U.S., Canada, U.K., Germany, France, Italy, Spain, Japan, China, India, South Korea, Australia, Brazil, Mexico, Argentina, Colombia, South Africa, United Arab Emirates, Saudi Arabia

Report coverage

Revenue forecast, company share, competitive landscape, growth factors & trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2026. For this study, Grand View Research has segmented the global viscosupplementation market report based on product and region:

  • Product Outlook (Revenue, USD Million, 2015 - 2026)

    • Single injection

    • Three injection

    • Five injection

  • Regional Outlook (Revenue, USD Million, 2015 - 2026)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • France

      • Germany

      • Italy

      • Spain

    • Asia Pacific

      • China

      • Japan

      • India

      • South Korea

      • Australia

    • Latin America

      • Brazil

      • Mexico

      • Argentina

      • Colombia

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $5,950
Multi User (2-5) - $6,950
Enterprise Access - $8,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified